Arick Sabin, DO
Infectious Disease · la Crosse, WINPI 1700143229
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $117 of the $134 with a category attached, or 87.2%. Every reported general payment came from a single manufacturer, Insmed, Inc..
Across 3 payments — averaging $44.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$134
Across 8 payments — averaging $118,956 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Diasorin Inc.$943K
- Pfizer$9K
What the payments were for
- Food & beverage$11787%
- Education$1713%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 3 | $134 |
How this compares
$134 in reported general payments places this provider in the 65th percentile of 133 infectious disease providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 37 | $165,815 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 18 | $62,986 |
| DovatoDolutegravir Sodium/Lamivudine | 11 | $32,006 |
| DescovyEmtricitabine/Tenofov Alafenam | 13 | $28,063 |
| Cefadroxil | 51 | $3,372 |
| Vancomycin Hcl | 20 | $2,138 |
| Doxycycline Monohydrate | 51 | $1,165 |
| Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df | 11 | $921 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 27 | $477 |
| Amoxicillin | 29 | $199 |
| Ciprofloxacin Hcl | 14 | $126 |
| Fluconazole | 16 | $103 |
| Azithromycin | 18 | $59 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in la Crosse
- Deena Athasla Crosse$207
- David McNamarala Crosse$170
- James LevinMadison$167K
- Edward MoralesGreen Bay$82K
- Robert StrikerMadison$80K
- Shravan KethireddyMadison$22K
- Nasia SafdarMadison$22K
- David AndesMadison$20K
- David LetzerBrookfield$4K
- William TimmBrookfield$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.